Pegylated interferons for chronic hepatitis C virus infection: An indirect analysis of randomized trials

Journal of Viral Hepatitis

Volumn 15, Issue 8, 2008, Pages 551-570

  Chou, R ^a,b,c,d   Carson, S ^a,b   Chan, B K S ^a,b  

^a Oregon Evidence based Practice Center   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Department of Medicine ^*  (United States)

^d Mailcode BICC   (United States)

Author keywords

Antiviral agents; Hepatitis c virus; Interferon alfa 2a; Interferon alfa 2b; Meta analysis

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; AMANTADINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ANEMIA; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DEPRESSION; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG WITHDRAWAL; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DYSFUNCTION; MONOTHERAPY; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL DYSF; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; DRUG TOXICITY; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 63549116894     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2008.00984.x     Document Type: Article

References (56)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Ku- hnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-714.
2. Seeff LB. Natural history of chornic hepatitis C. Hepatology 2002; 36: S35-S46.
3. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep 1998; 47: 1-39.
4. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331-8.
5. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002; 36: S30-S34.
6. Nainan OV, Alter MJ, Kruszon-Moran D et al. Hepatitis C virus genotypes and viral concentratiosn in participants of a general population survey in the United States. Gastroenterology 2006; 131: 478-484.
7. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 5(Suppl. 1): S237-S244.
8. Chander G, Sulkowski MS, Jenckes MW et al. Treatment of chronic hepatitis C: a systematic review. Hepatology 2002; 5(Suppl. 1): S135-S144.
9. Kjaegard LL, Krogsgaard K, Gluud C. Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. BMJ 2001; 323: 1151-1155.
10. Poynard T, Leroy V, Cohard M et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778-789.
11. Shepherd J, Waugh N, Hewitson P. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a systematic review. Hepatology 2000; 36: S135-S144.
12. Foster GR. Review article: pegylated interferons: chemical and clinical differences. Aliment Pharmacol Ther 2004; 20(8): 825-830.
13. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C: 2002 - June 10-12, 2002. Hepatology 2002; 36(5) (Suppl. 1): S3-S20.
14. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 2004: 1147-1171.
15. Siebert U, Sroczynski G, German Hepatitis C Model GEHMO Group, HTA Expert Panel on Hepatitis C. Effectiveness and cost-effectiveness of initial combination therapy with inter- feron/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security. Int J Technol Assess Health Care 2005; 21(1): 55-65.
16. Shepherd J, Brodin HFT, Cave CB, Waugh NR, Price A, Gabbay J. Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Int J Technol Assess Health Care 2005; 21(1): 47-54.
17. Khuroo MS, Khuroo MS, Dahab ST. Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. [erratum appears in Aliment Pharmacol Ther 2004; 20(11-12): 1388]. Aliment Pharmacol Ther 2004; 20(9): 931-938.
18. Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2004; 8(39): iii-iv.
19. Zaman A, Fennerty MB, Keeffe EB. Systematic review: peginterferon vs. standard interferon in the treatment of chronic hepatitis C. Aliment Pharmacol Ther 2003; 18(7): 661-670.
20. Silva M, Poo JL, Wagner F et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatology 2006; 45(2): 204-213.
21. Sporea I, Danila M, Stirli R, Popescu A, Laza A, Baditoiu L. Comparative study concerning the efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in patients with chronic viral C hepatitis. J Gastrointestin Liver Dis 2006; 15(2): 125-130.
22. Glenny AM, Altman DG, Song F et al. Indirect comparisons of competing interventions. Health Technol Assess 2005; 9(26): 1-134.
23. Bucher H, Guyatt G, Griffith L, Walter S. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997; 50(6): 683-691.
24. Lindsay KL. Introduction to therapy of hepatitis C. Hepatology 2002; 5(Suppl. 1): S114-S120.
25. Poynard T, McHutchison J, Manns M et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C [see comment]. Gastroenterology 2002; 122(5): 1303-1313.
26. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Methods for Meta-Analysis in Medical Research. Chichester: John Wiley & Sons, Inc., 2000.
27. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21(11): 1539-1558.
28. Egger M, Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
29. Sharp SJ, Thompson SG, Altman DG. The relation between treatment benefit and underlying risk in meta-analysis. BMJ 1996; 313: 735-738.
30. R Development Core Team (2006) R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing.
31. Arizcorreta A, Brun F, Fernandez-Gutierrez C et al. Modifications of haematological series in patients co- infected with human immunodeficiency virus and hepatitis C virus during treatment with interferon and ribavirin: differences between pegylated and standard interferon. Clin Microbiol Infect 2004; 10(12): 1067-1074.
32. Chung RT, Andersen J, Volberding P et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351(5): 451-459.
33. Fargion S, Borzio M, Maraschi A, Cargnel A, Gruppo Epa- tologico L. Triple antiviral therapy in HCV positive patients who failed prior combination therapy. World J Gastroenterol 2006; 12(33): 5293-5300.
34. Mangia A, Ricci GL, Persico M et al. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C. J Viral Hepat 2005; 12(3): 292-299.
35. Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351(5): 438-450.
36. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa- 2 a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347(13): 975-982.
37. 7. Alfaleh FZ, Hadad Q, Khuroo MS et al. Peginterferon alpha- 2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver Int 2004; 24(6): 568-574.
38. Bruno S, Camma C, Di Marco V et al. Peginterferon alfa-2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J Hematology 2004; 41(3): 474-481.
39. Carrat F, Bani-Sadr F, Pol S et al. Pegylated interferon alfa- 2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292(23): 2839-2848.
40. Crespo M, Sauleda S, Esteban JI et al. Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients. J Viral Hepat 2007; 14(4): 228-238.
41. Derbala M, Amer A, Bener A, Lopez AC, Omar M, El Ghannam M. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. J Viral Hepat 2005; 12(4): 380-385.
42. Laguno M, Murillas J, Blanco JL et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004; 18(13): F27-F36.
43. Lee SD, Yu ML, Cheng PN et al. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. J Viral Hepat 2005; 12(3): 283-291.
44. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358(9286): 958-965.
45. Scotto G, Fazio V, Palumbo E, Cibelli DC, Saracino A, An- garano G. Treatment of genotype lb HCV-related chronic hepatitis: efficacy and toxicity of three different interferon alfa-2b/ribavirin combined regimens in naive patients. New Microbiol 2005; 28(1): 23-29.
46. Tsubota A, Arase Y, Someya T et al. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype lb and high viral load. J Med Virol 2005; 75(1): 27-34.
47. Zeuzem S, Diago M, Gane E et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127(6): 1724-1732.
48. Chou R, Fu R, Huffman LH, Korthuis PT. Initial highly- active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect analyses. Lancet 2006; 368: 1503-1515.
49. Deeks JJ, Dinnes J, D'Amico R et al. Evaluating non-randomized intervention studies. Health Technol Assess 2003; 7(27): 1-192.
50. Ioannidis JP, Evans SJ, Gotzsche PC et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004; 141(10): 781-788.
51. Di Bisceglie AM, Rustgi VK, Thuluvath P et al. Pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2A or alfa-2B with ribavirin in treatment naive patients with genotype 1 chronic hepatitis C. Hepatology 2004; 40(Supp 4): 734A.
52. The IDEAL Study: A major clinical study for patients with hepatitis C. 2006 (cited; Available from: http://www.idealstudy.com/index.html.
53. Hadziyannis SJ, Sette H, Morgan TR et al. Peginterferon- alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140(5): 346-355.
54. Gartlehner G, Hansen RA, Nissman D, Lohr KN, Carey TS. A simple and valid tool distinguished efficacy from effectiveness studies. } Clin Epidemiol 2006; 59: 1040-1048.
55. Pegasys product label. USA: Roche, 2005. Available at http://www.rocheusa.com/products/pegasys/pi.pdf.
56. PEG-Intron product label. Schering Plough, 2005. Available at http://www.spfiles.com/pipeg-intron.pdf.